Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25943435 | 0.92 | STING1 (0.79) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21989983 | 0.92 | STING1 (0.88) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL25943410 | 0.90 | STING1 (0.77) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21990174 | 0.90 | STING1 (0.68) | STING1CPT2CPT1ACPT1BKLKB1 | |
| SCHEMBL21990015 | 0.88 | STING1 (0.82) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL20594650 | 0.88 | STING1 (1.00) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL25943416 | 0.88 | STING1 (0.80) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21990014 | 0.88 | STING1 (0.83) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21990118 | 0.86 | STING1 (0.78) | STING1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21990105 | 0.86 | STING1 (0.78) | STING1SMN1; SMN2CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170120-A1 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-29 | — | — | US | disclosed |
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170120-A1 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | STING1, MAVS, IRF3 | STING1 1/4885SMN1; SMN2 3171/4885CPT2 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.